Nutex Health, Inc.
NUTXNASDAQHealthcare● Active
$134.41
+$1.82(+1.37%)
Market Cap$800320958
P/E Ratio—
52W High$193.07
52W Low$77.21
Nutex Health, Inc. (NUTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NUTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$6.52
Est. $3.99 · +63.4%
Revenue
$0.22B
Est. $0.23B · -5.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
NUTX reports quarterly as a NASDAQ-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $4.88 | — | — | — | $0.21B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | $3.99 | $6.52 | +63.4% | $0.22B | $0.23B | -5.0% |
| ▼ Q1 FY2026 | Mar 5, 2026 | $5.56 | $1.61 | -71.0% | $0.15B | $0.26B | -41.4% |
| ▲ Q4 FY2025 | Nov 19, 2025 | $1.81 | $7.76 | +328.7% | $0.27B | $0.21B | +25.3% |
| ▼ Q4 FY2025 | Oct 22, 2025 | -$1.43 | -$2.95 | -105.8% | $0.24B | $0.24B | -0.0% |
| ▼ Q2 FY2025 | May 13, 2025 | $3.04 | $2.56 | -15.8% | $0.21B | $0.13B | +57.8% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.12 | $11.12 | +9366.7% | $0.26B | $0.08B | +217.6% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -$0.24 | -$1.72 | -616.7% | $0.08B | $0.07B | +7.6% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$4.88
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$6.52
EPS Est.
$3.99
EPS Surpr.
+63.4%
Revenue
$0.22B
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
$1.61
EPS Est.
$5.56
EPS Surpr.
-71.0%
Revenue
$0.15B
Q4 FY2025
Nov 19, 2025Beat
EPS Actual
$7.76
EPS Est.
$1.81
EPS Surpr.
+328.7%
Revenue
$0.27B
Q4 FY2025
Oct 22, 2025Miss
EPS Actual
-$2.95
EPS Est.
-$1.43
EPS Surpr.
-105.8%
Revenue
$0.24B
Q2 FY2025
May 13, 2025Miss
EPS Actual
$2.56
EPS Est.
$3.04
EPS Surpr.
-15.8%
Revenue
$0.21B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
$11.12
EPS Est.
-$0.12
EPS Surpr.
+9366.7%
Revenue
$0.26B
Q4 FY2024
Nov 8, 2024Miss
EPS Actual
-$1.72
EPS Est.
-$0.24
EPS Surpr.
-616.7%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $4.70 | $4.94 | $5.22 | 2 |
| Q3 FY2027 | $5.77 | $6.07 | $6.42 | 1 |
| Q2 FY2027 | $5.65 | $5.94 | $6.28 | 1 |
| Q1 FY2027 | $6.39 | $6.72 | $7.11 | 2 |
| Q4 FY2026 | $4.67 | $4.92 | $5.20 | 2 |
| Q3 FY2026 | $2.97 | $4.93 | $6.17 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.3B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.3B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.3B | 3 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +63.4% | $112.02 | $119.20 | +6.41% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -71.0% | $108.44 | $105.34 | -2.86% |
| ▲ Q4 FY2025 | Nov 19, 2025 | +328.7% | $99.20 | $112.19 | +13.09% |
| ▼ Q4 FY2025 | Oct 22, 2025 | -105.8% | $114.50 | $114.31 | -0.17% |
| ▼ Q2 FY2025 | May 13, 2025 | -15.8% | $124.64 | $125.93 | +1.03% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +9366.7% | $51.68 | $47.03 | -9.00% |
| ▼ Q4 FY2024 | Nov 8, 2024 | -616.7% | $28.89 | $31.56 | +9.24% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +75.9% | $7.83 | $7.90 | +0.89% |
Q2 FY2026+6.41%
Report Date
Apr 30, 2026
EPS Beat/Miss
+63.4%
Price Before
$112.02
Price After
$119.20
Q1 FY2026-2.86%
Report Date
Mar 5, 2026
EPS Beat/Miss
-71.0%
Price Before
$108.44
Price After
$105.34
Q4 FY2025+13.09%
Report Date
Nov 19, 2025
EPS Beat/Miss
+328.7%
Price Before
$99.20
Price After
$112.19
Q4 FY2025-0.17%
Report Date
Oct 22, 2025
EPS Beat/Miss
-105.8%
Price Before
$114.50
Price After
$114.31
Q2 FY2025+1.03%
Report Date
May 13, 2025
EPS Beat/Miss
-15.8%
Price Before
$124.64
Price After
$125.93
Q1 FY2025-9.00%
Report Date
Mar 31, 2025
EPS Beat/Miss
+9366.7%
Price Before
$51.68
Price After
$47.03
Q4 FY2024+9.24%
Report Date
Nov 8, 2024
EPS Beat/Miss
-616.7%
Price Before
$28.89
Price After
$31.56
Q3 FY2024+0.89%
Report Date
Aug 8, 2024
EPS Beat/Miss
+75.9%
Price Before
$7.83
Price After
$7.90
Avg Beat Reaction+2.85%
Avg Miss Reaction+1.81%
Beat Rate4 / 8 quarters
Largest Move+13.09% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NUTX ends December
Nutex Health, Inc. (NUTX) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $6.52 — beating the analyst consensus of $3.99 by +63.4%. The next NUTX earnings date is expected around September 1, 2026.
Each quarter, investors track NUTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NUTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NUTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NUTX earnings · 5 questionsNutex Health, Inc.'s next earnings report is expected around September 1, 2026. NUTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NUTX historically reports after market close (AMC).
NUTX earnings datewhen is NUTX earningsNUTX next earnings datewhen does NUTX report earningsNUTX earnings calendar
▸ Source: FMP · Nutex Health, Inc. SEC filings · US GAAP · Nutex Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026